Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
November 23, 2021 14:39 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
November 19, 2021 15:34 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals logo
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
October 04, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s...
Picture2.jpg
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
September 21, 2021 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Equillium_Square_Logo.png
Equillium to Present at Investor Conferences in November 2020
November 10, 2020 08:35 ET | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
logo.png
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
November 09, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
Equillium_Square_Logo.png
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
September 17, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
CRBP-300-196.png
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
November 05, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Nov. 8th at 8:30 AM ET - Norwood, MA, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
New Elsevier Book Examines Complex Mechanisms Relating to Cardiac Diseases from Pathophysiological and Clinical Viewpoints
April 05, 2017 04:00 ET | Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - April 05, 2017) - Elsevier, the information analytics company specializing in science and health, today announced the publication of The Heart in Rheumatic, Autoimmune...
red.jpg
RedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26, 2015
February 19, 2015 08:00 ET | RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...